Exploring the effect of dapagliflozin on coronary inflammation in type 2 diabetes patients based on the coronary artery perivascular fat attenuation index
Authors' conclusion
Dapagliflozin treatment is associated with a significant reduction in coronary artery inflammation in T2DM patients, which may partly explain its beneficial effects on reducing cardiovascular risk.
Study context
- Population
- T2DM patients undergoing coronary computed tomography angiography (CCTA) at Hebei Provincial People's Hospital, January 2021 to November 2024
- Participants
- 271 patients
- Exposure
- Dapagliflozin treatment vs no dapagliflozin
- Dapagliflozin+n = 103
- Dapagliflozin-n = 168reference
- Outcome
- Pericoronary FAI
Methodological detailssingle-centre, multiple linear regression
- Single-centre
- Multiple linear regression
Main finding
As reported in the abstract
Β (multiple linear regression), fat attenuation index (FAI) LAD
−2.449
P values are all less than 0.05
dapagliflozin+
Β (multiple linear regression), FAI RCA
−3.897
P values are all less than 0.05
dapagliflozin+
Observational data: associations, not effects.
Further findings
Baseline characteristics
- Dapagliflozin+ patients were younger
- P < 0.001
- Higher proportion of men in dapagliflozin+
- P < 0.05
- No between-group differences in diabetes course, BMI, blood lipid status
- P > 0.05
Subgroups
- Association differed across subsets of T2DM patients
Original publication
Exploring the effect of dapagliflozin on coronary inflammation in type 2 diabetes patients based on the coronary artery perivascular fat attenuation index. Cardiovasc Diabetol. Published 18 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →